Zhejiang Hisun Pharmaceutical Registers Cancer Drug in China

MT NewswiresJan 10 14:53

Express News | Zhejiang Hisun Pharmaceutical: Everolimus tablets have obtained pharmaceutical registration certificates.

BreakingsJan 9 17:08

Zhejiang Hisun Pharmaceutical (600267.SH): plans to invest 50 million yuan in Jisheng Aoma's capital increase.

On December 27, Gelonghui reported that Zhejiang Hisun Pharmaceutical (600267.SH) announced that Nanjing Jisheng Aoma Biomedical Co., Ltd. (referred to as "Jisheng Aoma") was established in 2021, and its main product indications include allergic rhinitis, allergic dermatitis, respiratory infections, vaccine adjuvants, etc. To support its own Innovative Drugs development, Jisheng Aoma recently plans to raise no more than 0.1 billion yuan. Given that the disease areas of Jisheng Aoma's pipeline products align with the company's Global Strategy, to promote cooperation with Jisheng Aoma and advance the company’s own Innovative Drugs development, it is agreed that the company will participate in this round of capital increase with its self-raised funds amounting to 50 million yuan, if...

Gelonghui FinanceDec 27, 2024 17:13

Zhejiang Hisun Pharmaceutical (600267): Improvement in operational margins and upgrade of the synthetic biology platform.

The operation situation has marginally improved, with the net income attributable to the parent company reaching a record high after excluding non-recurring items. As the impact of not winning bids in the multi-national centralized procurement gradually becomes apparent, the company's operating situation has significantly improved. In the first three quarters of 2024, the company achieved a net income of 5.15.

Western SecuritiesDec 27, 2024 16:07

Express News | The opening of the tenth batch of national Pharmaceutical centralized purchasing has prompted nearly 30 listed companies to announce their products are likely to be selected after the market close.

BreakingsDec 13, 2024 21:24

Zhejiang Hisun Pharmaceutical (600267.SH): Apremilast tablets and posaconazole enteric-coated tablets are expected to win centralized procurement bidding.

Zhejiang Hisun Pharmaceutical (600267.SH) announced that on December 12, 2024, the company participated in a joint procurement...

Zhitong FinanceDec 13, 2024 19:08